Checkpoint Inhibitors Clinical Trial Pipeline Insights | 180+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space | medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.
Cell-free DNA concentration is significantly increased in the first 2 weeks after surgery but these higher levels do not seem to interfere with monitoring of circulating tumor DNA for prognostic purposes.
The first randomized trial of a disease-modifying therapy in radiological isolated syndrome, the earliest pre-clinical phase of MS, suggests dimethyl fumarate reduced the risk of a first clinical event by 80%.
The Changing Face of Multiple Sclerosis: Addressing the Demographic Shift Towards Elderly Patients healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
BEDMINSTER, N.J., March 8, 2021 /PRNewswire/ Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, announced today the appointment of Luca Rastelli, Ph.D. as Chief Scientific Officer. Reporting directly to the Chief Executive Officer, Dr. Rastelli will lead all aspects of R&D for Jubilant Therapeutics and serve as a scientific liaison for the company to investors, partners and the medical community. Luca is a highly accomplished scientist and oncology drug developer and it is a pleasure to welcome him to the team, said Syed Kazmi, Ph.D., President and Chief Executive Officer of Jubilant Therapeutics. His experience and leadership advancing novel targeted therapeutics will be integral as we execute our corporate vision.